Stock Market Reviews

HIMS (Hims & Hers Health, Inc.) News

Get the latest news, insights, and market updates on HIMS (Hims & Hers Health, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Hims & Hers Agrees To Buy Eucalyptus In $1.15 Bil Deal. Stock Rallies.
  Him stock rose after the telehealth company announced that it had agreed to acquire Eucalyptus in a $1.15 billion deal.
  Feb 19, 2026 - $HIMS
• These Stocks Are Today’s Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More
  Walmart stock falls after the world’s largest retailer by revenue posts better-than-anticipated earnings.
  Feb 19, 2026 - $HIMS
• Do You Think Hims & Hers Health (HIMS) is Positioned for Long-Term Growth?
  Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Small Cap Growth Fund”. You can download a copy of the letter here. Small-cap stocks delivered marginal gains in the fourth quarter of 2025. The Russell 2000® Value Index outperformed the Russell 2000® Growth Index in the quarter, […]
  Feb 18, 2026 - $HIMS
• Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot
  Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased FDA scrutiny over compounded medications and has been referred to the US Department of Justice regarding possible marketing of unapproved drugs. Following these developments, Hims & Hers is shifting focus toward longevity and peptide related offerings. Hims & Hers Health, a telehealth platform...
  Feb 18, 2026 - $HIMS
• Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
  In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the previous day.
  Feb 18, 2026 - $HIMS
• Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal
  Hims & Hers Health, Inc. (NYSE:HIMS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best healthcare stocks on our list. TheFly reported on February 10 that Deutsche Bank lowered its price target on HIMS to $31 from $42 and maintained a Hold rating on […]
  Feb 18, 2026 - $HIMS
• 2 Profitable Stocks on Our Watchlist and 1 We Ignore
  Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
  Feb 17, 2026 - $HIMS
• Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk
  Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.
  Feb 17, 2026 - $HIMS
• Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus
  Novo Nordisk has filed a lawsuit against Hims & Hers Health accusing it of infringing patents related to its obesity drugs. The case targets compounded, low cost weight loss pills that Novo Nordisk argues are unauthorized copies of its treatments. The dispute puts a spotlight on how branded drugmakers respond to copycat obesity medications and on how these products are regulated and priced in the U.S. For investors following Novo Nordisk (CPSE:NOVO B), the legal move comes at a time when...
  Feb 16, 2026 - $HIMS
• Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for
  Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Feb 16, 2026 - $HIMS